RESEARKA

The mechanistic evidence that dominates this corpus—spanning in-vitro senescence-induction models, SASP profiling, and pathway-level analyses—has not been matched by equivalent clinical-efficacy data for the most translationally relevant claims. Coppe 2008 characterized senescence-associated secretory phenotypes under atmospheric vs. 3% O₂ culture conditions; Victorelli 2023 demonstrated that apoptotic stress drives mitochondrial DNA release during replicative senescence; and Bartlett 2024 showed that TPR is required for cytoplasmic chromatin fragment formation. These mechanistic findings provide biologically plausible pathways through which senescent cells may drive tissue dysfunction. No study in the corpus prospectively demonstrated that pharmacologically reducing senescent-cell burden in humans improves a patient-reported functional endpoint or delays time-to-disability by a clinically meaningful amount—a threshold that, for gait speed, has been set at 0.1 m/s (Perera 2006). The mechanistic-to-clinical gap therefore remains the single largest limitation of the current senescence-effects evidence base.

Citation Support

• source_1 Murray 2025
• source_2 Mielke 2025
• source_3 Zumerle 2024
• source_4 Mury 2025
• source_5 Zhao 2024